Dawn Schottland
SVP, Investor Relations and Corporate Affairs
Replay available
Geron Corporation (GERN) Q2 2026 Earnings Call
Geron Corporation (NASDAQ: GERN) Q2 2026 earnings conference call, held 2026-08-05. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Harout Semerjian
Chief Executive Officer
Ahmed ElNawawi
Chief Commercial Officer
Joseph Eid
Executive Vice President, Research and Development and Chief Medical Officer
Michelle Robertson
Chief Financial Officer
Tara Bancroft
Analyst, TD Cowen
Emily Bodnar
Analyst, HC Wainwright
Stephen Willie
Analyst, Stifel
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Geron Corporation.
Replay transcript excerpt
WEBVTT 00:00:00.051 -- 00:00:05.155 Hello and welcome to the Geron Corporation second quarter 2026 earnings 00:00:05.155 -- 00:00:09.918 call. At this time, all participants are in a listen-only mode. 00:00:09.918 -- 00:00:13.561 After the speaker's presentation, there will be a question and answer session. 00:00:13.561 -- 00:00:18.784 To ask a question during the session, you will need to press star 11 on your telephone. 00:00:18.784 -- 00:00:22.887 You will then hear an automated message advising your hand is raised. 00:00:22.887 -- 00:00:26.550 To withdraw your question, please press star 11 again. 00:00:26.550 -- 00:00:30.317 Please be advised that today's conference is being recorded. 00:00:30.317 -- 00:00:35.380 I would now like to turn the call over to Dawn Schottland, SVP, 00:00:35.380 -- 00:00:39.361 Investor Relations and Corporate Affairs. 00:00:42.343 -- 00:00:48.487 Good morning, everyone. Welcome to the Geron Corporation second quarter of 2026 earnings 00:00:48.487 -- 00:00:53.970 conference call. Before we begin, please note that during the course of this presentation 00:00:53.970 -- 00:00:58.292 and question and answer session, we will be making forward-looking statements regarding 00:00:58.292 -- 00:01:03.718 future events, performance, plans, expectations, and other projections, 00:01:03.718 -- 00:01:09.160 including those related to our 2026 financial guidance, our current Rytelo commercialization 00:01:09.160 -- 00:01:14.421 strategy and related opportunities in the US and the EU, the therapeutic potential 00:01:14.421 -- 00:01:20.183 of Rytelo, other anticipated clinical and commercial events and related timelines, 00:01:20.183 -- 00:01:24.844 the sufficiency of our financial resources, and other statements that are not historical 00:01:24.844 --...